Core Viewpoint - The company has recently received a patent certificate from the National Intellectual Property Administration for an invention related to a paclitaxel derivative and its preparation method, which enhances the quality control and pharmacological activity of paclitaxel-based anticancer compounds [1] Group 1: Patent Details - The patent is titled "A Paclitaxel Derivative and Its Preparation Method, Application" with patent number ZL 2023 1 1469030.2 [1] - The invention pertains to the field of medicinal chemistry, specifically focusing on a paclitaxel derivative that can be used for detecting impurities in paclitaxel-based anticancer compounds [1] Group 2: Benefits of the Invention - The compound provided by the invention can significantly reduce the toxicity or side effects of paclitaxel-based anticancer drugs and improve their long-term stability [1] - Controlling the content of the paclitaxel derivative has notable benefits for enhancing the pharmacological activity of the drug [1] Group 3: Strategic Implications - The acquisition of this patent reflects and extends the company's core technology [1] - While the patent will not have a significant immediate impact on the company's operations, it is beneficial for enhancing the company's intellectual property protection system and promoting technological innovation [1] - This development is expected to strengthen the company's core competitiveness through the utilization of proprietary technology [1]